Current consensus for the treatment of HER2-positive (human epidermal growth factor receptor 2) advanced breast cancer (ABC) is that anti-HER2 therapy should be offered first-line to all patients, unless contraindicated (1). Here, ERBB2 is linked to breast cancer.